Sunday 18 October 2026
Export FULC’s income statement to Excel — free account
Fulcrum Therapeutics, Inc.
FULC Healthcare Biotechnology
Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023. In the quarter to June 2026, EPS fell 21.4% and free cash flow fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.65
0.02
−0.54%
Follow FULC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (32.38%) | (27.10%) | (25.30%) | (31.21%) |
+8 more TTM periods Free account |
|
| (30.75%) | (25.83%) | (23.89%) | (28.80%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(27.20%) | (22.98%) | (21.56%) | (36.02%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.86) | (0.84) | (0.96) | (0.97) | |
Free Cash Flow |
(65.69) | (63.88) | (60.61) | (60.43) | |
Capital Expenditures |
0.09 | (0.32) | (0.54) | (0.40) | |
| Other line items | |||||
Cash ROIC |
(10.43%) | (9.58%) | (8.64%) | (15.15%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 0.84 | 0.80 | 0.84 | |
Depreciation/Fixed assets |
0.00 | 0.55 | 0.49 | 0.45 | |
Capex/Depreciation |
0.07 | (0.23) | (0.39) | (0.29) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.86) | (0.83) | (0.95) | (0.96) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates